Brussels, 21 December 2017
Investment Plan for Europe: EIB lends to AMW GmbH in Warngau
The European Investment Bank (EIB) is providing EUR 25 million to AMW GmbH (AMW). AMW is a specialist pharmaceutical company that specializes in novel drug delivery systems. With the money, AMW will be able to develop innovative drug expansion, clinical trials and expand production capacity at its plant in Warngau, Upper Bavaria, as well as at its subsidiary Endomedica (Halle, Saxony-Anhalt). A new building for research, development and production with special manufacturing technology and state-of-the-art laboratory equipment is to be built at the company headquarters in Warngau.
The transaction with AMW was made possible by the support of the European Fund for Strategic Investments (EFSI). EFSI is the central pillar of the Investment Plan for Europe, underwhich the EIB Group and the European Commission aimto act asstrategic partners to boost the competitiveness of the European economy.
EIB Vice-President Ambroise Fayolle, responsible for lending in Germany, said: “Promoting research, development and innovation with important health effects is one of the key concerns of the European Investment Bank. Our loan to AMW, backed by an EFSI guarantee, clearly shows what Europe is doing for sustainable growth and jobs.” He added: “This is the first funding for AMW. Our long loan maturities benefit an innovative company operating in an area that significantly improves people’s lives.”
Dr. Wilfried Fischer, Founder and Managing Director of AMW, commented: “AMW has an increasing pipeline of advanced-stage R&D projects close to market entry generating additional financing needs. We have been looking for an R&D-focused type of financing for quite some time, and believe that this dedicated programme is a perfect match for sustaining our growth rate by addressing the unmet needs of patients with severe diseases. With the acceleration of the R&D projects, we are confident of our ability to act asamajor player in new drug delivery systems in multi-billion euro target markets like diabetes or breast cancer – based and growing in the European Union. Speed is key for pharmaceutical markets and together with the EIB we are able to enter the next stage ofour company’s growth.”
European Commissioner Vytenis Andriukaitis, responsible for Health and Food Safety, said: “This is a concrete example of what the European Union can do for its citizens. Supporting R&D and clinical research contributes significantly to developing and producing new and innovative medicines for patients.”
The European Investment Bank (EIB) is the long-term lending institution of the European Union. Its shareholders are the EU Member States. It makes long-term finance available for sound investment in order to achieve EU policy goals.
AMW GmbH is an innovative, rapidly expanding specialty pharmaceuticals company located in Warngau near Munich, Germany. Its R&D expertise is focused on drug delivery systems, especially biodegradable implants and transdermal delivery systems.
Investment Plan for Europe
The Investment Plan for Europe, the Juncker Plan, is one of the EU’s most important actions to boost investment in Europe, thereby creating jobs and boosting growth. To this end, existing and new funding will be used more intelligently. The EIB Group plays a key role in this Investment Plan. Guarantees from the European Fund for Strategic Investments (EFSI) enable the EIB and the EIF to take on a larger share of the project risk, making it easier for private lenders to participate in the projects as well. In addition to the EFSI, there is the new Advisory Service EIAH, which helps public and private promoters to structure investment projects more professionally. The Investment Plan is also intended to create a more investment-friendly legal framework in the EU. This is especially true in the digital, energy and capital markets sectors. In December 2017, the European Parliament and the Member States decided to extend the duration of EFSI and increase financial capacity.